Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Convertible Debt: 2020

  • Whitehawk Therapeutics' Convertible Debt was N/A to $1.1 million in Q4 2020 from the same period last year, while for Dec 2020 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $1.1 million for FY2020, which is N/A change from last year.
  • Per Whitehawk Therapeutics' latest filing, its Convertible Debt stood at $1.1 million for Q4 2020.
  • Whitehawk Therapeutics' Convertible Debt's 5-year high stood at $1.1 million during Q4 2020, with a 5-year trough of $1.1 million in Q4 2020.
  • In the last 1 years, Whitehawk Therapeutics' Convertible Debt had a median value of $1.1 million in 2020 and averaged $1.1 million.